Summary: Treatment of t2 diabetes has been undergoing dynamic devel-opment in recent years. The completion of numerous large clinical trials and the results obtained from their systematic analysis required a change in the recommendations for pharmacotherapy. New-generation drugs, mainly SGLT-2 inhibitors and GLP-1 receptor agonists, have been promoted from drugs used occasionally and being a "curiosity" for particular patients in clinical practice, to the group of first-line drugs used together with or added to metformin.
Due to modification in the recommendation of the Polish Diabetes Association for the treatment of patients with t2 diabetes with high or very high cardiovascular risk, primary care physicians will be forced to change the mindset regarding treatment options, the use of specific groups and drugs in strictly defined clinical indications and their implementation in this group of patients.